Summary
Clinical evidence accumulated over the past decade suggests that neurohormonal mechanisms significantly influence the pathogenesis and eventual outcome of congestive heart failure (CHF). Pharmacologic modulation of this neuroendocrine activity can, consequently, be expected to improve patient prognosis. Results of several recent clinical trials—the Studies of Left Ventricular Dysfunction (SOLVD), the second Veterans Administration Cooperative Vasodilator Heart Failure Trial (VHeFT-II), and the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)—provide substantial evidence that addition of the angiotensin-converting enzyme (ACE) inhibitor enalapril to conventional therapeutic regimens can significantly reduce mortality and improve prognosis in patients with all grades of heart failure. Moreover, data from all three trials confirm the involvement of neurohormonal systems in the development and progression of CHF and suggest that the beneficial effects of enalapril in heart failure may in part be due to the suppression of this neurohormonal activity. It is now apparent that some form of neurohormonal activation is present early in the course of the disease before the emergence of overt heart failure symptoms. On the basis of such findings, it would seem that early introduction of therapy targeted at neurohormonal influences may well become a central component of any future CHF treatment program.
Similar content being viewed by others
References
Packer M. Neurohormonal interactions and adaptations in congestive heart failure.Circulation 1988;77:721–730.
Francis G. Neurohormonal mechanisms involved in congestive heart failure.Am J Cardiol 1985;55:15A-21A.
Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure.Am J Cardiol 1978;41:233–243.
Levine TB, Francis GS, Goldsmith SR, et al. Activity of the sympathetic nervous system and the renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure.Am J Cardiol 1982;49:1659–1666.
Francis GS, Goldsmith SR, Levine TB, et al. The neurohormonal axis in congestive heart failure.Ann Intern Med 1984;101:370–377.
Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure.N Engl J Med 1984;311:819–823.
Rector TS, Olivari MT, Levine TB, et al. Predicting survival for an individual with congestive heart failure using plasma norepinephrine concentrations.Am Heart J 1987;114:148–152.
Brown JJ, Davies JL, Johnson VW, et al. Renin relationships in congestive heart failure, treated and untreated.Am Heart J 1970;80:329–342.
Dzau VJ, Colucci WS, Hollenberg NK, et al. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.Circulation 1981;63:645–651.
Francis G, Benedict C, Johnstone D, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure.Circulation 1990;82:1721–1729.
Burnett J, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in CHF in the human.Science 1986;2321:1145–1147.
Hara H, Oghira T, Shima J, et al. Plasma atrial natriuretic peptide level as an index for the severity of congestive heart failure.Clin Cardiol 1987;10:437–442.
Gottlieb S, Kukin ML, Ahern D, et al. Prognostic importance of atrial natriuretic factor in patients with chronic heart failure.J Am Coll Cardiol 1989;13:1534–1539.
Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics.Br Heart J 1987;57:17–22.
Broqvist M, Dahlstrom U, Karlberg BE, et al. Neuroendocrine response in acute failure and the influence of treatment.Eur Heart J 1989;10:1075–1083.
Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure.Lancet 1987;2:709–711.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure.N Engl J Med 1987;316:1429–1435.
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality.Circulation 1990;82:1730–1736.
SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med 1991;325:293–302.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.Lancet 1993;342:821–828.
Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.N Engl J Med 1991;325:303–310.
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study.N Engl J Med 1986;314:1547–1552.
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial (SAVE).N Engl J Med 1992;327:669–677.
Kromer EP, Elsner D, Riegger GAJ. Digoxin, converting enzyme inhibitor (quinapril) and the combination in patients with congestive heart failure functional class II and sinus rhythm.J Cardiovasc Pharmacol 1990;16:9–14.
Esler M, Jackman G, Bobik A, et al. Determination of norepinephrine apparent spillover rate and clearance in human.Life Sci 1979;25:1461–1470.
McCance AJ, Forfar JC. Selective enhancement of the cardiac sympathetic response to exercise by anginal chest pain in humans.Circulation 1989;80:1642–1651.
Akselrod S, Gordon D, Ubei FA, Shannon DV, Barger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: A quantitative probe of beat-to-beat cardiovascular control.Science 1981;231:220–222.
Binder T, Frey B, Porenta G, et al. Prognostic value of heart rate variability in patients awaiting cardiac transplantation.Pace 1992;15:2215–2220.
Kleiger RO, Miller JP, Bigger JT, Moss AJ, and the Multicenter Post Infarction Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction.Am J Cardiol 1987;59:256–262.
Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease.N Engl J Med 1971;285:877–882.
La Rovere MT, Mortara A, Specchia G, Schwartz PJ. Myocardial infarction and baroreflex sensitivity. Clinical studies.G Ital Cardiol 1991;22:639–645.
Flapan AD, Nolan J, Neilson JM, Ewing DJ. Effect of captopril on cardiac parasympathetic activity in chronic heart failure secondary to coronary heart disease.Am J. Cardiol 1992;69:532–535.
Binkley PF, Haas GJ, Starling RC, et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure.J Am Coll Cardiol 1993;21:655–661.
Vagelos R, Nejedly M, Wilson K, et al. Comparison of low versus high dose enalapril therapy for patients with severe congestive heart failure (CHF).J Am Coll Cardiol 1991;2:275.
Riegger GAJ. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure.J Cardiovasc Pharmacol 1990;15(Suppl 2):S41-S46.
Pouleur H, Rousseau MF, Oakley C, Ryden L for the Xamoterol in Severe Heart Failure Study Group. Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure Study.Am J Cardiol 1991;68:71–74.
Cushman DW, Wang FL, Funk WK, et al. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiological important target organs.Am J Hypertens 1989;2:294–306.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Coats, A.J.S., Adamopoulos, S. Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure. Cardiovasc Drug Ther 8, 685–692 (1994). https://doi.org/10.1007/BF00877115
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00877115